SEQENS

Executive Summary

SEQENS is an integrated global leader in pharmaceutical solutions, personal care, and specialty ingredients, operating as a Contract Development and Manufacturing Organization (CDMO) and specialty chemical producer. With 16 production sites and 9 R&D centers worldwide, the company focuses on small molecule APIs, intermediates, excipients, and custom specialties. Its emphasis on innovation and sustainability positions it as a key partner for pharmaceutical companies seeking reliable, high-quality manufacturing. Established in 2017, SEQENS has rapidly built a broad service offering from early development to commercial production, leveraging its global footprint to serve diverse markets. The CDMO market is experiencing strong demand driven by increased outsourcing and complexity of drug molecules. SEQENS is well-poised to capture this growth through ongoing investments in capacity and technology. The company's integrated model, combining small molecule expertise with drug delivery capabilities, provides a competitive edge in addressing customer needs for complex formulations. While privately held, SEQENS's strategic expansions and partnerships are anticipated to drive revenue growth. The company's focus on sustainability and innovation aligns with industry trends, making it a attractive partner for long-term collaborations.

Upcoming Catalysts (preview)

• Q2 2026Announcement of major capacity expansion at a European facility75% success
• Q3 2026Signing of a long-term supply agreement with a top-20 pharma company60% success
• Q4 2026Launch of a new drug delivery platform for oral formulations50% success